NOTICE OF INTENT TO INCORPORATE NON-FSS (OPEN MARKET) ITEMS OVER $25k ON GSA ORDER

The Food and Drug Administration is issuing a notice of intent to incorporate non-Federal Supply Schedule (open market) items totaling $103,374.42 into a Blanket Purchase Agreement under GSA procurement procedures, with a maximum potential contract value of $9.6 million. The procurement aims to acquire a turn-key laboratory solution comprising specialized instrumentation and software from Agilent Technologies, including the 1290 Infinity III Fluorescence Detector, OpenLab CDS Workstation Plus Software, Headspace Control Software, preventive maintenance kits, waste management assemblies, and a custom-configured computer workstation from Software House International—all to be delivered and installed at the FDA facility in Rockville, Maryland. The notice specifies that all non-Schedule items must be clearly labeled as open-market line items and that price reasonableness must be documented in accordance with FAR Part 12, FAR 8.401, and GSAR Subpart 538.71, with compliance required for public posting under FAR 5.101(a)(1). The solicitation number is 75F40126Q132815, with a response deadline of July 24, 2026, and all inquiries must be directed to Contracting Officer Suzanne Martella via email. The agreement will be structured as a single-award BPA under GSA Federal Supply Schedule authorities, though no formal CLINs, pricing breakdowns, delivery schedules, inspection criteria, packaging standards, or evaluation factors are detailed in this notice. Offerors are expected to adhere to commercial item acquisition rules, with no socioeconomic set-asides or specific certifications required at this stage, and no COR or COTR has been identified. The total estimated value of the open-market components is separate from the broader BPA ceiling, and actual pricing will be determined prior to award execution.